273 related articles for article (PubMed ID: 32079264)
1. p53-Related Transcription Targets of TAp73 in Cancer Cells-Bona Fide or Distorted Reality?
Wang C; Teo CR; Sabapathy K
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079264
[TBL] [Abstract][Full Text] [Related]
2. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
[TBL] [Abstract][Full Text] [Related]
3. CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer.
Malik N; Yan H; Yang HH; Ayaz G; DuBois W; Tseng YC; Kim YI; Jiang S; Liu C; Lee M; Huang J
PLoS Genet; 2021 May; 17(5):e1009553. PubMed ID: 33945523
[TBL] [Abstract][Full Text] [Related]
4. JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
Kostecka A; Sznarkowska A; Meller K; Acedo P; Shi Y; Mohammad Sakil HA; Kawiak A; Lion M; Królicka A; Wilhelm M; Inga A; Zawacka-Pankau J
Cell Death Dis; 2014 Oct; 5(10):e1484. PubMed ID: 25341038
[TBL] [Abstract][Full Text] [Related]
5. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression.
Saifudeen Z; Diavolitsis V; Stefkova J; Dipp S; Fan H; El-Dahr SS
J Biol Chem; 2005 Jun; 280(24):23094-102. PubMed ID: 15805112
[TBL] [Abstract][Full Text] [Related]
7. Dichotomous transactivation domains contribute to growth inhibitory and promotion functions of TAp73.
Li D; Kok CYL; Wang C; Ray D; Osterburg S; Dötsch V; Ghosh S; Sabapathy K
Proc Natl Acad Sci U S A; 2024 May; 121(21):e2318591121. PubMed ID: 38739802
[TBL] [Abstract][Full Text] [Related]
8. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
Si H; Lu H; Yang X; Mattox A; Jang M; Bian Y; Sano E; Viadiu H; Yan B; Yau C; Ng S; Lee SK; Romano RA; Davis S; Walker RL; Xiao W; Sun H; Wei L; Sinha S; Benz CC; Stuart JM; Meltzer PS; Van Waes C; Chen Z
Oncogene; 2016 Nov; 35(44):5781-5794. PubMed ID: 27132513
[TBL] [Abstract][Full Text] [Related]
9. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
Vayssade M; Haddada H; Faridoni-Laurens L; Tourpin S; Valent A; Bénard J; Ahomadegbe JC
Int J Cancer; 2005 Oct; 116(6):860-9. PubMed ID: 15849742
[TBL] [Abstract][Full Text] [Related]
10. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells.
Yu J; Baron V; Mercola D; Mustelin T; Adamson ED
Cell Death Differ; 2007 Mar; 14(3):436-46. PubMed ID: 16990849
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
12. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
13. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
Gomes S; Raimundo L; Soares J; Loureiro JB; Leão M; Ramos H; Monteiro MN; Lemos A; Moreira J; Pinto M; Chlapek P; Veselska R; Sousa E; Saraiva L
Cancer Lett; 2019 Apr; 446():90-102. PubMed ID: 30664963
[TBL] [Abstract][Full Text] [Related]
14. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
15. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.
Nakagawa T; Takahashi M; Ozaki T; Watanabe K; Hayashi S; Hosoda M; Todo S; Nakagawara A
Cancer Lett; 2003 Jul; 197(1-2):105-9. PubMed ID: 12880968
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.
Dar AA; Belkhiri A; Ecsedy J; Zaika A; El-Rifai W
Cancer Res; 2008 Nov; 68(21):8998-9004. PubMed ID: 18974145
[TBL] [Abstract][Full Text] [Related]
17. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
18. Transactivation-dependent and -independent regulation of p73 stability.
Dulloo I; Sabapathy K
J Biol Chem; 2005 Aug; 280(31):28203-14. PubMed ID: 15919663
[TBL] [Abstract][Full Text] [Related]
19. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
[TBL] [Abstract][Full Text] [Related]
20. Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway.
Wang J; Xie H; Gao F; Zhao T; Yang H; Kang B
Tumour Biol; 2016 Mar; 37(3):4203-12. PubMed ID: 26490992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
